Multiple reaction monitoring, a highly specific and sensitive mass-spectrometry technique, can detect and quantify analytes from plasma, serum and other biological samples.

A multiplex assay can simultaneously measure multiple analytes, such as proteins, peptides, metabolites and lipids.

“The ability to quickly and accurately measure, monitor and analyze a large number of protein biomarkers in a single test has important applications for understanding human diseases and developing new clinical diagnostics,” said John E. Blume, Ph.D., chief science officer of Applied Proteomics.

Blume continued, “Agilent’s innovation in mass spectrometry is an important part of this collaboration as we work together to expand the capabilities of multiplex protein assays.”

Applied Proteomics specializes in a proteomics platform solution with mass spectrometry-based systems control and computational expertise to rapidly collect, process and analyze proteins.

Proteomics is the study of the structure and function of proteins and how they interact within a complex biological system.

“We are thrilled to be collaborating with Applied Proteomics, an organization that has leading expertise in developing mass spectrometry-based methods and instrumentation technologies for protein quantification and proteome applications,” said Can Ozbal, director of Agilent’s RapidFire business.